Literature DB >> 28009685

There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center.

Shailja C Shah1, Steven Naymagon, Benjamin L Cohen, Bruce E Sands, Marla C Dubinsky.   

Abstract

BACKGROUND AND GOALS: Despite published clinical guidelines, substantive data underlying the approach to the management of hospitalized ulcerative colitis (UC) patients failing outpatient therapy are lacking. Variability in practice is therefore not uncommon and may impact clinical outcomes. The degree of variability, however, is not well-studied. Our aim was to evaluate variability in management of the hospitalized UC patient to inform future efforts targeting care optimization for this high-risk population. STUDY: An internet survey was distributed among inflammatory bowel disease providers, which included: (1) nonvignette-based questions assessing provider demographics, experience, and practice setting; (2) diagnostic and therapeutic practice patterns based on a vignette of a hospitalized UC patient. Descriptive and univariate analyses were performed.
RESULTS: Ninety-one percent of eligible individuals were included. Nearly 97% endorsed confidence in management of hospitalized UC patients. In general, 83% initiate intravenous corticosteroids (IVCS) as initial therapy, whereas 17% initiate infliximab (IFX) (+/-IVCS). At IVCS failure in the vignette, 74% initiated IFX, 15% increased IVCS dose, 7% initiated cyclosporine, and 4% chose colectomy. Of those choosing IFX, 65% chose 5 mg/kg as the initial dose, whereas the remainder chose 10 mg/kg. Twenty-eight percent gave an additional IFX 5 mg/kg and 7% gave an additional 10 mg/kg dose to the patient in the vignette not responding to 5 mg/kg.
CONCLUSIONS: Even among experienced inflammatory bowel disease providers, there is significant practice pattern variability in the management of hospitalized UC patients. Future efforts should target this variability. Adjunctively, prospective trials are needed to guide appropriate therapeutic algorithms, especially with respect to positioning and optimally dosing IFX in this population.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28009685      PMCID: PMC6658167          DOI: 10.1097/MCG.0000000000000779

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis.

Authors:  S Sebastian; S Myers; S Nadir; S Subramanian
Journal:  Dig Dis Sci       Date:  2018-12-07       Impact factor: 3.199

2.  Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis.

Authors:  Niharika Nalagatla; Katherine Falloon; Gloria Tran; Nienke Z Borren; Danny Avalos; Jay Luther; Francis Colizzo; John Garber; Hamed Khalili; Joanna Melia; Matthew Bohm; Ashwin N Ananthakrishnan
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-23       Impact factor: 11.382

3.  AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.

Authors:  Joseph D Feuerstein; Kim L Isaacs; Yecheskel Schneider; Shazia Mehmood Siddique; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2020-01-13       Impact factor: 22.682

4.  AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.

Authors:  Siddharth Singh; Jessica R Allegretti; Shazia Mehmood Siddique; Jonathan P Terdiman
Journal:  Gastroenterology       Date:  2020-01-13       Impact factor: 22.682

5.  Practice pattern variability in the management of acute severe colitis: a UK provider survey.

Authors:  Shaji Sebastian; Jessica Lisle; Sreedhar Subramanian; Anjan Dhar; Achut Shenoy; Jimmy Limdi; Jeffrey Butterworth; Patrick B Allen; Sunil Samuel; Gordon Moran; Richard Shenderey; Gareth Parkes; Tim Raine; Alan J Lobo; Nicholas A Kennedy
Journal:  Frontline Gastroenterol       Date:  2019-08-17

Review 6.  Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough.

Authors:  Aderson Omar Mourão Cintra Damião; Natália Sousa Freitas Queiroz
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

7.  Endocrinology practice patterns of hypothyroidism and osteoporosis management in a U.S. tertiary academic medical center.

Authors:  Jien Shim; Tiffany Lin; Cody Dashiell-Earp; Meghan Nechrebecki; Angela M Leung
Journal:  Clin Diabetes Endocrinol       Date:  2019-07-18

8.  Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease.

Authors:  Shirley Cohen-Mekelburg; Beth I Wallace; Tony Van; Wyndy L Wiitala; Shail M Govani; Jennifer Burns; Rachel Lipson; Huifeng Yun; Jason Hou; James D Lewis; Jason A Dominitz; Akbar K Waljee
Journal:  JAMA Netw Open       Date:  2021-03-01

Review 9.  Ulcerative Colitis: Current and Emerging Treatment Strategies.

Authors:  Maia Kayal; Shailja Shah
Journal:  J Clin Med       Date:  2019-12-30       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.